Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MEDP
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
MEDP
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

MEDP Revenue Forecast

MEDP EPS Forecast

MEDP FAQs

What is bull’s view on MEDP?

Medpace (MEDP) is currently trading at $332.23, with a Zacks Rank of #2 (Buy), reflecting positive earnings revisions. Analysts expect a 20.73% year-over-year EPS growth to $2.97 and a 7.62% revenue increase to $536.37M in the upcoming report, signaling strong operational performance. The stock's forward P/E of 27.94 suggests a premium valuation, but its consistent growth trajectory supports bullish sentiment.

What is bear's view on MEDP?

MEDP stock closed at $348.97 on January 31, 2025, with a slight decline of 0.25%. The bearish view stems from its high valuation, with a forward P/E of 27.94, significantly above the industry average of 16.25, and a PEG ratio of 1.78, indicating overvaluation despite strong earnings growth. Additionally, recent price weakness (-2.63% monthly) suggests limited near-term upside.

What is MEDP revenue forecast for next quarter？

The market consensus for MEDP's revenue in the upcoming quarter is projected to be approximately $539.739M USD.

MEDP VS S&P500

Medpace's small and midsize biopharma customers are very dependent on outsourced clinical trials since they do not have the capacity to run trials in-house.

Medpace's operational discipline should support strong earnings growth and high returns as the company continues to expand.

Medpace is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies.

Ask Intellectia about MEDP

MEDP Analyst's Forecast

Eric Coldwell

Baird

Hold

Price Target

$349 → $354

Upside

+4.79%

Baird raised the firm's price target on Medpace to $354 from $349 and keeps a Neutral rating on the shares. The firm said the sector chop, political headlines galore, and presently weak biotech funding each keep them more guarded than normal. Yet this is exactly the type of company that long-term investors should crave and the firm has a very positive long-term bias on the shares.
Charles Rhyee

TD Cowen

Strong Buy

Price Target

$413 → $372

Upside

+12.7%

Eric Coldwell

Baird

Buy → Hold

Price Target

$413 → $349

Upside

+5.74%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free